Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

Inclusion Criteria:

* 1\. A clinical diagnosis of external anogenital/perianal warts with at least 2 warts and no more than 20 warts located in one or more of the following anatomic locations:

  1. In both sexes: inguinal, perineal, and perianal areas
  2. In men: penis shaft, scrotum, glans penis and foreskin
  3. In women: on the vulva
* 2\. Subjects has a total wart areas of at least 10 mm2, but not more than 500 mm2
* 3\. Female subjects of childbearing potential must be confirmed not pregnant by a negative urine pregnancy test prior to trial treatment

Exclusion Criteria:

* 1\. Subject has received any topical and/or destructive treatments for external anogenital warts within 4 weeks (within 12 months for imiquimod and within 12 weeks for sinecatechins) prior to enrolment
* 2\. Subject suffer from any of the following conditions:

  1. Known human immunodeficiency virus (HIV) infection
  2. An outbreak of herpes genitalis in the wart areas within 4 weeks prior to enrolment
  3. Has internal (rectal urethral, vaginal/cervical) warts that require or are undergoing treatment
  4. Has a dermatological disease (e.g. psoriasis) or skin condition in the wart areas
* 3\. Subjects using systemic virostatic compounds or immunosuppressive medication within 30 days prior to enrollment
* 4\. Prior quadrivalent HPV vaccination